DOCS vs. ILMN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at DOCS and ILMN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | DOCS | ILMN |
|---|---|---|
| Company Name | Doximity, Inc. | Illumina, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Technology | Life Sciences Tools & Services |
| Market Capitalization | 9.49 billion USD | 19.04 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | June 24, 2021 | July 28, 2000 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of DOCS and ILMN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | DOCS | ILMN |
|---|---|---|
| 5-Day Price Return | -6.45% | -1.17% |
| 13-Week Price Return | -27.62% | 20.11% |
| 26-Week Price Return | -13.67% | 43.77% |
| 52-Week Price Return | -9.92% | -11.66% |
| Month-to-Date Return | -29.67% | -3.46% |
| Year-to-Date Return | -13.05% | -10.75% |
| 10-Day Avg. Volume | 2.97M | 1.60M |
| 3-Month Avg. Volume | 1.63M | 1.80M |
| 3-Month Volatility | 43.40% | 63.28% |
| Beta | 1.49 | 1.39 |
Profitability
Return on Equity (TTM)
DOCS
23.90%
Health Care Technology Industry
- Max
- 48.09%
- Q3
- 42.04%
- Median
- 18.65%
- Q1
- 11.64%
- Min
- 11.05%
DOCS’s Return on Equity of 23.90% is on par with the norm for the Health Care Technology industry, indicating its profitability relative to shareholder equity is typical for the sector.
ILMN
29.98%
Life Sciences Tools & Services Industry
- Max
- 23.81%
- Q3
- 11.79%
- Median
- 7.51%
- Q1
- 3.14%
- Min
- -6.95%
ILMN’s Return on Equity of 29.98% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
DOCS
40.72%
Health Care Technology Industry
- Max
- 52.24%
- Q3
- 49.36%
- Median
- 34.00%
- Q1
- 16.86%
- Min
- 13.38%
DOCS’s Net Profit Margin of 40.72% is aligned with the median group of its peers in the Health Care Technology industry. This indicates its ability to convert revenue into profit is typical for the sector.
ILMN
16.39%
Life Sciences Tools & Services Industry
- Max
- 33.77%
- Q3
- 17.97%
- Median
- 8.97%
- Q1
- 3.80%
- Min
- -11.89%
ILMN’s Net Profit Margin of 16.39% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
DOCS
39.72%
Health Care Technology Industry
- Max
- 74.05%
- Q3
- 65.47%
- Median
- 33.33%
- Q1
- 22.83%
- Min
- 21.46%
DOCS’s Operating Profit Margin of 39.72% is around the midpoint for the Health Care Technology industry, indicating that its efficiency in managing core business operations is typical for the sector.
ILMN
18.07%
Life Sciences Tools & Services Industry
- Max
- 31.55%
- Q3
- 21.26%
- Median
- 14.06%
- Q1
- 8.54%
- Min
- 0.11%
ILMN’s Operating Profit Margin of 18.07% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | DOCS | ILMN |
|---|---|---|
| Return on Equity (TTM) | 23.90% | 29.98% |
| Return on Assets (TTM) | 20.66% | 11.36% |
| Net Profit Margin (TTM) | 40.72% | 16.39% |
| Operating Profit Margin (TTM) | 39.72% | 18.07% |
| Gross Profit Margin (TTM) | 90.20% | 66.74% |
Financial Strength
Current Ratio (MRQ)
DOCS
7.79
Health Care Technology Industry
- Max
- 7.79
- Q3
- 6.49
- Median
- 6.03
- Q1
- 3.62
- Min
- 2.96
DOCS’s Current Ratio of 7.79 is in the upper quartile for the Health Care Technology industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
ILMN
1.43
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.87
- Median
- 1.75
- Q1
- 1.37
- Min
- 0.57
ILMN’s Current Ratio of 1.43 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
DOCS
0.00
Health Care Technology Industry
- Max
- 0.14
- Q3
- 0.10
- Median
- 0.01
- Q1
- 0.00
- Min
- 0.00
Falling into the lower quartile for the Health Care Technology industry, DOCS’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
ILMN
0.84
Life Sciences Tools & Services Industry
- Max
- 0.95
- Q3
- 0.70
- Median
- 0.45
- Q1
- 0.18
- Min
- 0.00
ILMN’s leverage is in the upper quartile of the Life Sciences Tools & Services industry, with a Debt-to-Equity Ratio of 0.84. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
DOCS
--
Health Care Technology Industry
- Max
- 224.12
- Q3
- 224.12
- Median
- 219.00
- Q1
- 219.00
- Min
- 219.00
Interest Coverage Ratio data for DOCS is currently unavailable.
ILMN
-2.28
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
ILMN has a negative Interest Coverage Ratio of -2.28. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | DOCS | ILMN |
|---|---|---|
| Current Ratio (MRQ) | 7.79 | 1.43 |
| Quick Ratio (MRQ) | 7.26 | 1.03 |
| Debt-to-Equity Ratio (MRQ) | 0.00 | 0.84 |
| Interest Coverage Ratio (TTM) | -- | -2.28 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
DOCS
0.00%
Health Care Technology Industry
- Max
- 0.77%
- Q3
- 0.62%
- Median
- 0.19%
- Q1
- 0.05%
- Min
- 0.00%
DOCS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
ILMN
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.02%
- Q3
- 0.67%
- Median
- 0.32%
- Q1
- 0.00%
- Min
- 0.00%
ILMN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
DOCS
0.00%
Health Care Technology Industry
- Max
- 101.92%
- Q3
- 87.10%
- Median
- 42.63%
- Q1
- 10.66%
- Min
- 0.00%
DOCS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
ILMN
0.00%
Life Sciences Tools & Services Industry
- Max
- 97.67%
- Q3
- 61.34%
- Median
- 18.53%
- Q1
- 0.00%
- Min
- 0.00%
ILMN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | DOCS | ILMN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
DOCS
37.52
Health Care Technology Industry
- Max
- 225.71
- Q3
- 183.85
- Median
- 51.77
- Q1
- 45.26
- Min
- 35.02
In the lower quartile for the Health Care Technology industry, DOCS’s P/E Ratio of 37.52 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
ILMN
26.37
Life Sciences Tools & Services Industry
- Max
- 78.22
- Q3
- 57.42
- Median
- 34.18
- Q1
- 28.39
- Min
- 1.55
In the lower quartile for the Life Sciences Tools & Services industry, ILMN’s P/E Ratio of 26.37 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
DOCS
15.28
Health Care Technology Industry
- Max
- 117.92
- Q3
- 92.41
- Median
- 15.08
- Q1
- 8.11
- Min
- 6.06
DOCS’s P/S Ratio of 15.28 aligns with the market consensus for the Health Care Technology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
ILMN
4.32
Life Sciences Tools & Services Industry
- Max
- 10.69
- Q3
- 6.37
- Median
- 4.95
- Q1
- 3.27
- Min
- 1.04
ILMN’s P/S Ratio of 4.32 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
DOCS
12.51
Health Care Technology Industry
- Max
- 115.01
- Q3
- 89.39
- Median
- 9.75
- Q1
- 4.04
- Min
- 3.06
DOCS’s P/B Ratio of 12.51 is within the conventional range for the Health Care Technology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
ILMN
5.93
Life Sciences Tools & Services Industry
- Max
- 8.12
- Q3
- 5.04
- Median
- 3.94
- Q1
- 2.12
- Min
- 1.13
ILMN’s P/B Ratio of 5.93 is in the upper tier for the Life Sciences Tools & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | DOCS | ILMN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 37.52 | 26.37 |
| Price-to-Sales Ratio (TTM) | 15.28 | 4.32 |
| Price-to-Book Ratio (MRQ) | 12.51 | 5.93 |
| Price-to-Free Cash Flow Ratio (TTM) | 30.41 | 18.53 |